Shareholders of Arena Pharmaceuticals (ARNA) endured a significant drop in share prices last month only to see shares win back some of their gains this month after the company announced the departure of its co-founder and CEO.
Although a fresh set of eyes in the C-suite could begin to repair the significant damage done to shareholder value over the past few years, the company's challenges extend far beyond its leadership and, without a major cost-cutting program, the struggles facing Arena Pharmaceuticals makes it too risky of a stock to buy.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
